Creating a direct link between manufacturers and patients.
Serving ultra-orphan patients is unlike anything else in the pharmaceutical industry. Distribution and financial models can be greatly affected by the small size of the ultra-orphan market. The task can seem overwhelming: How do you improve your chances of getting your drug approved by the FDA? And once you gain approval, what’s the best distribution method to patients? Finally, how do you find these unique patients and grow your market?
Centric Health Resources has created a revolutionary model allowing you to bypass traditional channels and distribute products directly to consumers. This direct distribution model virtually eliminates the costs and resources generally associated with multiple touch points for getting the specialty therapy into the hands of the patient. As a result, the price of the drug remains transparent and stable, without unnecessary mark-up along the way that typically inflates the costs for patients and payers. In addition, attractive pricing reflects efficiencies associated with integration as well as lower overhead.
Empowering benefits to ultra-orphan patients – and you. Our unique distribution model addresses the complex needs of the ultra-orphan drug marketplace, responding to market forces that span margin pressures, patient needs and increased requirements to track patient data and report outcomes. It also allows you as a manufacturer, the opportunity to demonstrate value to patients, physicians and payers, adapt to a changing regulatory environment, and garner support from the patient community by engaging advocacy groups as partners in the provision of services. To enhance your development and distribution processes, we can also help you with:
- Converting Risk Evaluation Mitigation Strategies (REMS) into a competitive advantage instead of a time-consuming obstacle for drug approval
- Removing as many barriers between you and ultra-orphan patients as possible
- Reimbursement strategies and support
- Health management
- Detailed custom reporting and data management
- Program management
- Growing your patient market through public awareness, patient advocacy and physician education.
Centric Health Resources is the exclusive provider of the PROLASTIN DIRECT® program for patients with alpha-1 antitrypsin deficiency in the United States. We are proud to care for the largest identified group of patients with alpha-1 in the U.S. through this program.
Watch The Prolastin Direct Story
to learn more: